Pemetrexed had significantly better clinical efficacy in patients with stage IV lung adenocarcinoma with susceptible EGFR mutations receiving platinum-based chemotherapy after developing resistance to the first-line gefitinib treatment.

Onco Targets Ther · 2016 · PMC4803239 · PMID 27051298

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In line with their finding, our study showed a trend for better PFS and a significantly longer OS in patients receiving platinum-based chemotherapy than those receiving non-platinum-based chemotherapy.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.